April 7 Operations (monthly target 5%–10%, low frequency, core recognition, profit-making effect, casual orders)

StrawberryIce · 2026-04-07T22:09:21+00:00

The market generally rose today, with profit-taking concentrated in the chemical and pharmaceutical sectors. Overall, I am holding a bearish position. Tomorrow, focus on the performance of targets like JinYao Pharmaceutical and be cautious of stocks with poor earnings, which may indicate a major market move is approaching.

StrawberryIce

2026-04-07 22:09:21

Abstract generation in progress

Today’s market overview
The tendency to make money is concentrated in areas such as chemicals, pharmaceuticals, sports, optical fibers, PCB, and other different directions. It reflects a market-wide weak rebound rotation pattern.
In terms of position and structure, some are distributed in consecutive limit-up stocks and high-position trend structures, represented by Tianjin Phama Industry, Xinengtai Shan, FaErSheng, GuoSheng Technology, and others.

Today’s trades
No position

Tomorrow’s plan
1, Most likely continue staying in cash. Watch Tianjin Phama Industry’s performance after the regulatory scrutiny, and also Wanbangde, which today managed to contain the unusual fluctuation, then observe how it performs tomorrow.
2, If external events don’t get resolved, big capital will just be hesitant and cautious. Also, April is a month when earnings are concentrated and tend to have mishaps—pay attention to stocks with earnings losses. Lately, I’m increasingly suspecting that GJD is using this geopolitical conflict to draw a big-market K-line and build a base. It feels like a major market move is getting closer.
3, Tomorrow’s watchlist: Changfei Optical Fiber, Tianjin Phama Industry, Wanbangde, Guosheng Technology (I’m speechless—it’s too capable of running up), Xinengtai Shan / Huiyuan Communication (Changfei Optical Fiber’s little brother).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.